Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777868 | 0.83 | TSHR (0.39) | PTGS2KDM4EALDH1A1HPGDHTT | |
| SCHEMBL3784913 | 0.82 | PTGS2 (0.41) | PTGS2PTGS1KDM4EMEN1KMT2A | |
| SCHEMBL3788176 | 0.73 | PTGS2 (0.43) | PTGS2PTGS1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3782626 | 0.70 | TDP1 (0.38) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL3777364 | 0.70 | SMN1; SMN2 (0.39) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3777368 | 0.70 | SMN1; SMN2 (0.39) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3785180 | 0.69 | KDM4E (0.47) | PTGS1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL3776982 | 0.68 | KDM4E (0.39) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3778049 | 0.68 | TSHR (0.40) | PTGS2PTGS1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3779431 | 0.67 | PTGDR2 (0.37) | PTGS2PTGS1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | PTGS2 821/4885PTGS1 584/4885KDM4E 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.